Log in to save to my catalogue

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DN...

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DN...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d600d9b4f409474cb363cc7b8d335cf3

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

About this item

Full title

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

Publisher

Germany: BioMed Central Ltd

Journal title

Clinical epigenetics, 2024-01, Vol.16 (1), p.13-13, Article 13

Language

English

Formats

Publication information

Publisher

Germany: BioMed Central Ltd

More information

Scope and Contents

Contents

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis. It is marked by extraordinary resistance to conventional therapies including chemotherapy and radiation, as well as to essentially all targeted therapies evaluated so far. More than 90% of PDAC cases harbor an activating KRAS mutation. As the most common KRAS varia...

Alternative Titles

Full title

Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_d600d9b4f409474cb363cc7b8d335cf3

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d600d9b4f409474cb363cc7b8d335cf3

Other Identifiers

ISSN

1868-7083,1868-7075

E-ISSN

1868-7083,1868-7075

DOI

10.1186/s13148-024-01623-z

How to access this item